Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00546260 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Adjunctive Antiplatelet Therapy Prior to Primary PCI in Patients With STEMI
A Phase 2 study, sponsored by Alexion Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT00546260 is a Phase 2 study that was terminated before completion, run by Alexion Pharmaceuticals. The registered enrollment target is 70 participants.
The verdict
NCT00546260, a Phase 2 study, was terminated before completion, sponsored by Alexion Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
Safety and efficacy of adjunctive antiplatelet therapy prior to primary percutaneous intervention (PCI) in patients with ST-Elevation Myocardial Infarction (STEMI)
Interventions
- DRUG placebo
- DRUG PRT060128 Potassium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2007-11 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00546260
The ClinicalTrials.gov registry entry for NCT00546260 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00546260 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00546260 about?
NCT00546260 is a clinical study titled "Safety and Efficacy Study of Adjunctive Antiplatelet Therapy Prior to Primary PCI in Patients With STEMI". Safety and efficacy of adjunctive antiplatelet therapy prior to primary percutaneous intervention (PCI) in patients with ST-Elevation Myocardial Infarction (STEMI)
What is the current status of trial NCT00546260?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2007-11. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00546260?
The interventions under investigation include: placebo (DRUG), PRT060128 Potassium (DRUG).
Who is sponsoring clinical trial NCT00546260?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.